InsidersTradesSigma
Track the NovoCure Limited share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.1bn. The latest transaction was filed on 23 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: NICOLAS LEUPIN. All data is accessible without an account.
Analysts rate NovoCure Limited Buy (bullish), based on 7 analysts. Average price target: US$27.14.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
NovoCure Limited is a biotechnology company that develops treatments for cancer patients. It is listed on the NASDAQ under the symbol NVCR.